PBAC's latest decision on Pegfilgrastim: Recommended (2020). Considered for Chemotherapy-induced neutropenia in patients receiving chemotherapy with intention of achieving cure or substantial remission, who are at greater than 20% risk of developing febrile neutropenia or at substantial risk of prolonged severe neutropenia for ≥7 days.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
9
first 2006
Submissions
9
2006 → 2020
Eligible population
Cancer patients receiving chemotherapy with intention of achieving cure or substantial remission who are at greater than 20% risk of developing febrile neutropenia or substantial risk of prolonged severe neutropenia for ≥7 days.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Key trials
APO-Peg-02, APO-Peg-03
Comparator
Neulasta
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design. Submission assumed Pelgraz would be listed at same price as Neulasta with no net cost to Government.
ICER (historical)
$15k/QALY–$45k/QALY across 4 submissions (2006–2018) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.